Industry Strength Score
54/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
AURA BIOSCIENCES INC (AURA) Stock Price & Overview
NASDAQ:AURA • US05153U1079
Current stock price
7.01 USD
-0.04 (-0.57%)
At close:
7.01 USD
0 (0%)
After Hours:
The current stock price of AURA is 7.01 USD. Today AURA is down by -0.57%. In the past month the price increased by 7.19%. In the past year, price increased by 13.98%.
AURA Key Statistics
52-Week Range4.345 - 7.68
Current AURA stock price positioned within its 52-week range.
1-Month Range6.43 - 7.68
Current AURA stock price positioned within its 1-month range.
- Market Cap
- 449.692M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.79
- Dividend Yield
- N/A
AURA Stock Performance
Today
-0.57%
1 Week
-3.58%
1 Month
+7.19%
3 Months
+25.18%
Longer-term
6 Months +14.36%
1 Year +13.98%
2 Years -4.63%
3 Years -38.07%
5 Years N/A
10 Years N/A
AURA Stock Chart
AURA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to AURA. When comparing the yearly performance of all stocks, AURA is one of the better performing stocks in the market, outperforming 75.75% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
AURA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AURA. AURA has a great financial health rating, but its profitability evaluates not so good.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
AURA Earnings
Next Earnings DateMay 7, 2026
Last Earnings DateMar 30, 2026
PeriodQ4 / 2025
EPS Reported-$0.37
Revenue Reported
EPS Surprise 15.15%
Revenue Surprise %
AURA Forecast & Estimates
12 analysts have analysed AURA and the average price target is 20.81 USD. This implies a price increase of 196.83% is expected in the next year compared to the current price of 7.01.
Analysts
Analysts83.33
Price Target20.81 (196.86%)
EPS Next Y8.68%
Revenue Next YearN/A
AURA Index Membership
AURA is currently included in the following stock indexes tracked on ChartMill.
AURA Financial Highlights
Over the last trailing twelve months AURA reported a non-GAAP Earnings per Share(EPS) of -1.79. The EPS decreased by -2.29% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-106.19M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -62.68% | ||
| ROE | -77.56% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%28.85%
Sales Q2Q%N/A
EPS 1Y (TTM)-2.29%
Revenue 1Y (TTM)N/A
AURA Ownership
Ownership
Inst Owners76.65%
Shares64.15M
Float57.43M
Ins Owners2.52%
Short Float %3.51%
Short Ratio6.97
AURA Industry Overview
AURA operates in the Biotechnology sub-industry within the Health Care sector. This group contains 412 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
14/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
49%
Outperformed 49% of sub-industries
6 Month Rank
29%
Outperformed 29% of sub-industries
Industry Fundamentals & Breadth
- Members
- 412
- New Highs
- 4.6%
- New Lows
- 4.6%
- Average ROE
- 47%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.9%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.1
AURA Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 365.426B | ||
| AMGN | AMGEN INC | 13.88 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.44 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| INCY | INCYTE CORP | 10.61 | 19.286B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AURA
Company Profile
Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The company is headquartered in Boston, Massachusetts and currently employs 106 full-time employees. The company went IPO on 2021-10-29. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. The company is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a broad range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.
Company Info
IPO: 2021-10-29
AURA BIOSCIENCES INC
80 Guest Street
Boston MASSACHUSETTS US
CEO: Elisabet de los Pinos
Employees: 106
Phone: 16175008864
AURA BIOSCIENCES INC / AURA FAQ
Can you describe the business of AURA BIOSCIENCES INC?
Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The company is headquartered in Boston, Massachusetts and currently employs 106 full-time employees. The company went IPO on 2021-10-29. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. The company is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a broad range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.
What is the current price of AURA stock?
The current stock price of AURA is 7.01 USD. The price decreased by -0.57% in the last trading session.
Does AURA stock pay dividends?
AURA does not pay a dividend.
What is the ChartMill technical and fundamental rating of AURA stock?
AURA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of AURA BIOSCIENCES INC (AURA)?
AURA BIOSCIENCES INC (AURA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.79).
Is AURA BIOSCIENCES INC (AURA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AURA.
How many employees does AURA BIOSCIENCES INC have?
AURA BIOSCIENCES INC (AURA) currently has 106 employees.